Ember Therapeutics, Inc.

Equities

EMBT

US29082W1099

Delayed OTC Markets Other stock markets 10:02:31 2023-09-20 am EDT			5-day change	1st Jan Change
0.0001 ^USD	-.--%		-.--%	-.--%

2019	Viscogliosi Brothers LLC cancelled the acquisition of OP-1 Portfolio Program from Ember Therapeutics, Inc..	CI
2018	Viscogliosi Brothers LLC entered into a letter of intent to acquire OP-1 Portfolio Program from Ember Therapeutics, Inc..	CI

Ember Therapeutics, Inc. acquired Worldwide License of BMP-7 and OP-1 Portfolio from Stryker Corporation.

December 30, 2014

Ember Therapeutics, Inc. (OTCPK:EMBT) acquired Worldwide License of BMP-7 and OP-1 Portfolio from Stryker Corporation (NYSE:SYK) in 2014.

Ember Therapeutics, Inc. (OTCPK:EMBT) completed the acquisition of Worldwide License of BMP-7 and OP-1 Portfolio from Stryker Corporation (NYSE:SYK) in 2014.

Latest news about Ember Therapeutics, Inc.

Viscogliosi Brothers LLC cancelled the acquisition of OP-1 Portfolio Program from Ember Therapeutics, Inc..	19-08-15	CI
Viscogliosi Brothers LLC entered into a letter of intent to acquire OP-1 Portfolio Program from Ember Therapeutics, Inc..	18-08-15	CI
Ember Therapeutics, Inc. acquired the assets of of Dermasilk Brands, Inc. from Midwood Distributors, Inc. for $1.3 million.	16-09-07	CI
Knight Therapeutics Inc. and Ember Therapeutics, Inc. Expand Distribution Partnership	16-07-06	CI
Ember Therapeutics, Inc. entered into a definitive agreement to acquire the assets of Migralex, Inc. for $0.87 million.	16-03-20	CI
Ember Therapeutics, Inc. acquired ICX-RHY/Vavelta from Intercytex Limited for $1.1 million.	16-03-15	CI
American Home Alliance Corp will Change its Ticker to EMBT from AHLL	16-02-24	CI
AMERICAN HOME ALLIANCE CORP will Change its Name to Ember Therapeutics, Inc	16-02-24	CI
Ember Therapeutics, Inc. acquired American Home Alliance Corp. in a reverse merger transaction.	16-02-02	CI
Ember Therapeutics, Inc. Announces Initial Positive Results from a Phase 2 Trial of BMP-7	15-10-19	CI
Mariel Therapeutics, Inc. acquired Ember Therapeutics, Inc. from Third Rock Ventures II, L.P. of Third Rock Ventures II, L.P. and others for $6 million.	15-03-11	CI
Ember Therapeutics, Inc. acquired Worldwide License of BMP-7 and OP-1 Portfolio from Stryker Corporation.	14-12-30	CI
Ember Therapeutics, Inc. Announces Publication of Key Preclinical Data Demonstrating Inhibition of Transient Receptor Potential Vanilloid	12-09-27	CI
Ember Therapeutics, Inc. Announces Management Appointments	12-05-29	CI
Ember Therapeutics, Inc. Closes License Deal with Joslin Diabetes Center	12-03-31	CI

Chart Ember Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Sector

More about the company